Last reviewed · How we verify
MYO-029
At a glance
| Generic name | MYO-029 |
|---|---|
| Sponsor | Wyeth is now a wholly owned subsidiary of Pfizer |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Tolerability Study of FG-3019 in Participants With Idiopathic Pulmonary Fibrosis (PHASE1)
- Study Evaluating MYO-029 in Adult Muscular Dystrophy (PHASE1, PHASE2)
- Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of MYO-029 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MYO-029 CI brief — competitive landscape report
- MYO-029 updates RSS · CI watch RSS
- Wyeth is now a wholly owned subsidiary of Pfizer portfolio CI